AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

AbbVie says 55% of Crohn's patients reached remission in a late-stage study, boosting Skyrizi's outlook amid market competition. Latest Ratings for ABBV Date Firm Action From To Feb 2022 UBS Downgrades Buy Neutral Feb 2022 Mizuho Maintains Buy Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for ABBV View the Latest Analyst Ratings Importance Rank: 1 read more